Lisa Vanderpump's nephew, Sam Vanderpump, recently opened up about his ongoing health struggles. The 29-year-old Made in Chelsea star shared that he is still awaiting a liver transplant following his diagnosis of end-stage liver disease.
Sam announced his diagnosis publicly in October 2025. The announcement came months after he suffered severe liver and kidney failure following sepsis in December 2024. In an Instagram post, he shared that he "lives with a genetic liver condition and polycystic kidney disease (PKD)."
While appearing on the October 7 episode of Good Morning Britain, Sam said, "When I was first told that I needed a transplant, they said maybe [in] the next two years I'd have a transplant. I think we're already a year down the line, and luckily my health hasn't deteriorated. But that is the fear."
The reality star, who dyed his hair pink to raise awareness about organ donation, said he has received an overwhelming response from fans. However, he clarified that getting a transplant is not that simple. Sam explained that organ donation follows a "certain procedure" that he cannot arrange himself.
"So if someone were interested in being a live donor for me, they would have to contact the hospital, King's College Hospital, and go through that route themselves," he added. "So, it's kind of like you're caught between a rock and a hard place. You want to get further up the list, but you don't want your health to deteriorate."

#Health #hospital

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.

#palsonify

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $139 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.
Companies worth $10 billion or more are generally described as "large-cap stocks," and VRTX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. VRTX derives its primary competitive strength from its global monopoly in CF treatments, anchored by flagship blockbusters like Trikafta/Katori which generate robust cash flow to fuel its high-impact clinical pipeline.
Dear GameStop Stock Fans, Mark Your Calendars for September 8
SMCI vs. CoreWeave: 1 AI Infrastructure Model Has the Bigger Opportunity
Why **** ysts Think Sellas Life Sciences Stock Can Gain 150% From Here

#vrtx #massachusetts

Headquartered in Boston, Massachusetts, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops innovative medicines for serious diseases, including cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.
Moreover, the company is building beyond its approved treatments with potential therapies targeting genetic and other complex conditions, including kidney, metabolic, and neuromuscular diseases.
Here Is How to Play Tesla Stock After Its Robotaxi Breakthrough
Micron Stock Pullback: High Growth, Low Multiple Support Upside
Strategy Just Sold $334 Million in Shares to Build Cash and Buy Back Preferred Stock. This Hits MSTR Stock Holders With Dilution.

#including #headquartered

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM), which develops and commercializes therapies for patients with serious and rare diseases, detracted from the fund's performance during the quarter. On August 03, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $98.45 per share. The one-month return of Insmed Incorporated (NASDAQ:INSM) was -12.56%, and its shares lost 11.59% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $21.34 billion.
Baron Health Care Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated is a biotechnology company with three lead pulmonology ******* ets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite what we believe has been a strong start to the launch, shares fell after first quarter Brinsupri sales missed expectations as investors focused on early signs of higher treatment discontinuations. Insmed's exit from the Nasdaq-100 Index created additional technical selling pressure. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension and pulmonary hypertension ******* ociated with interstitial lung disease. Compared to existing inhaled prostanoids that require four daily treatments, once-daily TPIP is more convenient and can be dosed at significantly higher levels, potentially resulting in meaningfully better efficacy."

#fund #baron

Aug 3 (Reuters) - Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust ‌demand for its cystic fibrosis treatments.
The company expects its ‌annual revenue to be between $13.1 billion and $13.2 billion, compared with $12.95 billion to $13.1 billion previously. **** ysts on average expect 2026 revenue of $13.07 billion, according to data compiled by LSEG.
Vertex said its annual outlook excludes the pending Crinetics acquisition and that an updated forecast will be provided after the ‌deal closes, which is ⁠expected in the third quarter.
Here are more details:
• Vertex's $10 billion acquisition of Crinetics expands its reach beyond ⁠cystic fibrosis, adding endocrine disorders to a diversification strategy that already includes povetacicept in kidney, Casgevy in sickle cell and Journavx in pain, **** ysts had said.

#cystic #fibrosis

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now.
On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations.
VILevi/Shutterstock.com
The company plans to file the remaining modules and conclude the NDA application process during the latter half of 2026. The company highlighted that QTORIN rapamycin has attained FDA designations for Orphan Drug, Fast Track designations, and Breakthrough Therapy. The company is also speeding up U.S. launch preparation for a possible independent commercial launch in the early half of 2027, subject to approval.
Earlier on June 22, the company revealed that the FDA had provided a rolling review for QTORIN rapamycin's New Drug Application. Palvella Founder and CEO, Wes Kaupinen, highlighted that the company plans to use the Breakthrough Therapy, the benefits of rolling review, and Fast Track designations to facilitate an efficient route toward achieving FDA approval. He further stated:

SOUTHPORT, England — David Howard was age 7 when he was diagnosed with cystic fibrosis. By the time he was a teenager — well before recent medical advances for this rare genetic condition — he’d found out via internet searches he wasn’t expected to live beyond his mid-20s.
Imagine, then, how blessed this Irishman, now 27, feels to be walking the sun-kissed fairways of Royal Birkdale and about to take on the best golfers in the world at the British Open.
“Here I am, as healthy as ever and playing at the Open. It’s just nuts,” Howard said with a smile at the back of the 18th green after his first practice round, in the company of former champions Padraig Harrington and Shane Lowry. “Yeah, I’d like to think I’m an inspiration.”
Being a qualified mechanic and No. 1,456 in the world amateur rankings ensures Howard, who came through one of four local qualifying events to take his place in golf’s oldest major, is no normal British Open participant.
Also making him different is what he packs in his golf bag for each round: As important as his clubs is his medication, with Howard taking up to 30 tablets a day to prevent infection and help digest food properly.

Of the 156 players competing at this week's Open Championship, David Howard's journey to Royal Birkdale is among the most remarkable and inspiring.
For a long time, teeing it up at a major alongside the world's best golfers was nothing more than a pipe dream for the trained mechanic from county Cork.
When Howard was seven years old, he was diagnosed with cystic fibrosis, the genetic condition that causes sticky mucus to build up in the lungs and digestive system.
By his own estimate, Howard was in hospital "a few times a year" with infections.
"I remember when I first got access to a phone when I was 12, 13, I googled 'cystic fibrosis life expectancy' and it was saying mid-20s," the 27-year-old told BBC Sport NI's Stephen Watson.

Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street ****** ysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235.
The firm pointed to an upcoming data release for Insmed's experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).
According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.
The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed's drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.